Stryker (NYSE:SYK)‘s stock had its “hold” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday.

The analysts wrote, “SYK is acquiring ENTL for $24.00 per share (a 50% premium) or $662M of cash which is 7.1x consensus 2017E sales. ENTL is the leader in minimally invasive surgical (MIS) treatment of ear, nose, and throat (ENT) diseases and manufactures products that specifically cover nasal procedures. We think that the deal makes strategic and financial sense for SYK since it broadens SYK’s ENT offering and we expect ENTL’s sustained double-digit growth to be accretive to SYK’s overall growth in coming years.””

SYK has been the subject of a number of other research reports. Piper Jaffray Companies reiterated an “overweight” rating and issued a $148.00 price target on shares of Stryker in a report on Thursday, August 24th. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and increased their price target for the company from $161.00 to $173.00 in a report on Thursday, November 16th. BidaskClub downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. ValuEngine upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Zacks Investment Research downgraded shares of Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $152.10.

Stryker (NYSE:SYK) opened at $151.93 on Thursday. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. The stock has a market cap of $56,794.30, a PE ratio of 24.05, a PEG ratio of 2.39 and a beta of 0.78. Stryker has a twelve month low of $115.75 and a twelve month high of $160.62.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business’s revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.39 EPS. analysts forecast that Stryker will post 6.47 earnings per share for the current fiscal year.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the transaction, the insider now directly owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.40% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in SYK. Koch Industries Inc. boosted its stake in shares of Stryker by 34,120.3% during the 2nd quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock worth $1,252,000 after purchasing an additional 1,256,991 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Stryker by 5.2% during the 2nd quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock worth $3,208,017,000 after purchasing an additional 1,139,082 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Stryker by 2,237.8% during the 2nd quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock worth $141,452,000 after purchasing an additional 975,656 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Stryker by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock worth $3,341,643,000 after purchasing an additional 657,656 shares during the last quarter. Finally, APG Asset Management N.V. boosted its stake in shares of Stryker by 117.1% during the 3rd quarter. APG Asset Management N.V. now owns 583,736 shares of the medical technology company’s stock worth $82,902,000 after purchasing an additional 314,800 shares during the last quarter. 74.97% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/stryker-syk-rating-reiterated-by-needham-company-llc/1753370.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.